Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055957 | 0.85 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL20384172 | 0.84 | PTGS2 (0.53) | PTGS2PTGS1LMNAMEN1KMT2A | |
| SCHEMBL12469250 | 0.83 | PTGS2 (0.57) | PTGS2PTGS1LMNA | |
| SCHEMBL4618133 | 0.81 | SOS1 (0.54) | PTGS2PTGS1MEN1KMT2ATP53 | |
| SCHEMBL67606 | 0.81 | SOS1 (0.50) | PTGS2PTGS1MEN1KMT2ATP53 | |
| SCHEMBL27710777 | 0.81 | SOS1 (0.72) | PTGS2PTGS1LMNAMEN1KMT2A | |
| SCHEMBL8055954 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL646030 | 0.80 | PTGS2 (0.56) | PTGS2PTGS1KMT2A | |
| SCHEMBL755309 | 0.80 | LMNA (0.60) | PTGS2PTGS1LMNAMEN1KMT2A | |
| SCHEMBL30041432 | 0.80 | PTGS2 (0.56) | PTGS2PTGS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253335-A1 | SULFONYL-CONTAINING ARYL COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2022-12-08 | — | — | WO | disclosed |
| EP-2951169-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-28 | — | — | EP | disclosed |
| US-9926333-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-27 | — | — | US | disclosed |
| US-20170327514-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-16 | — | — | US | disclosed |
| US-9732093-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150368270-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-24 | — | — | US | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| EP-1765768-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| WO-2006136859-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| CN-1845894-A | phenoxyacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-10-11 | — | — | CN | disclosed |
| EP-1660431-A2 | PHENOXYACETIC ACID DERIVATIVES | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006040529-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006005909-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005018529-A2 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293352-A1 | Phenoxiacetic acid derivatives | HRH2, HRH1, HCAR2 | PTGS2 21/4885PTGS1 55/4885LMNA 2569/4885 |
| US-20170327514-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | PTGS2 32/4885PTGS1 14/4885LMNA 3996/4885 |
| US-20150368270-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | PTGS2 32/4885PTGS1 14/4885LMNA 3996/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | PTGS2 146/4885PTGS1 51/4885LMNA 4386/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | PTGS2 2677/4885PTGS1 2563/4885LMNA 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.